Leptoprol

Leuprorelin, the active ingredient in Leptoprol, is a Gonadotropin‑releasing hormone (GnRH) agonist presented as a sterile solution for subcutaneous use. It modulates hormone production and is employed in the management of several hormone‑dependent cancers and benign conditions in adult patients.

GNH USA supplies Leptoprol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards, manufactures under GMP conditions, and offers both bulk and unit‑dose shipments for global distribution.

Leuprorelin acts on the GnRH pathway to control hormone‑driven diseases.

- Prostate cancer: lowers testosterone levels to help control disease progression. - Endometriosis: suppresses estrogen production, reducing lesion growth and pain. - Uterine fibroids: decreases ovarian hormone stimulation, leading to fibroid shrinkage. - Precocious puberty: halts premature activation of the hypothalamic‑pituitary‑gonadal axis. - Breast cancer (adjuvant therapy): limits estrogen exposure, supporting adjuvant treatment. - Ovarian cancer (adjuvant therapy): reduces gonadotropin stimulation, complementing chemotherapy.

Leuprorelin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes - Injection site pain or erythema - Headache - Fatigue - Mood changes - Decreased libido

Serious or Rare Side Effects: - Cardiovascular events (e.g., myocardial infarction) - Severe allergic reactions (anaphylaxis) - Bone density loss leading to fractures - Liver function abnormalities - Hormonal withdrawal syndrome - Pituitary apoplexy (very rare)

When prescribing Leuprorelin, clinicians should observe several safety considerations. - Cardiovascular risk: assess history of heart disease before initiating therapy. - Bone health: monitor bone mineral density during long‑term treatment. - Diabetes mellitus: watch for alterations in glucose control. - Liver function: evaluate hepatic enzymes prior to and during therapy. - Pregnancy and lactation: avoid use in women who are pregnant or may become pregnant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Leuprorelin can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Anticoagulants: increased bleeding risk due to hormonal effects. - CYP3A4 inducers (e.g., rifampicin): may reduce drug exposure. - Hormone replacement therapy: antagonizes intended hormone suppression.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: possible changes in glucose levels. - Thyroid hormone replacement: monitor thyroid function tests. - Corticosteroids: may exacerbate bone loss. - Opioids: may mask pain related to disease progression. - NSAIDs: monitor for cardiovascular side effects.